









Markets
/
Stocks
/
nasdaq-coep
/

Coeptis Therapeutics Holdings Inc

COEP

14.640USD

-0.110-0.75%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

61.00MMarket Cap

LossP/E TTM



Coeptis Therapeutics Holdings Inc

14.640

-0.110-0.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Coeptis Therapeutics Holdings Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Coeptis Therapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking

222 / 407

Overall Ranking

458 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Coeptis Therapeutics Holdings Inc Highlights

StrengthsRisks

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Undervalued

The company’s latest PE is -3.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 146.21K shares, increasing 7.66% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 27.53K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.78, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.78

Change



Financials

5.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.57

Key Metrics

Free cash flow

No Data

Coeptis Therapeutics Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 5.87, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.92, which is -91.07% below the recent high of -0.35 and -21.93% above the recent low of -4.77.

Score

Industry at a Glance

Previous score

5.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 222/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.54, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 16.25 and the support level at 13.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.27

Change

0.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.242

Neutral

RSI(14)

44.509

Neutral

STOCH(KDJ)(9,3,3)

17.739

Sell

ATR(14)

0.750

High Vlolatility

CCI(14)

-134.300

Sell

Williams %R

93.000

Oversold

TRIX(12,20)

-0.140

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

15.066

Sell

MA10

15.141

Sell

MA20

15.258

Sell

MA50

14.829

Sell

MA100

12.601

Buy

MA200

11.352

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 3.03%, representing a quarter-over-quarter decrease of 87.46%. The largest institutional shareholder is The Vanguard, holding a total of 27.53K shares, representing 0.57% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Calise (Chris)

312.69K

Mehalick (David)

130.07K

Armistice Capital LLC

94.77K

Sheehy (Christine Elise)

50.53K

Yerace (Daniel Alexander)

45.53K

-9.89%

The Vanguard Group, Inc.

Star Investors

27.53K

+12.65%

Geode Capital Management, L.L.C.

20.28K

+1.56%

Salkind (Gene)

4.21K

Sea Otter Advisors LLC

2.25K

Steward Partners Investment Advisory, LLC

1.00K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.57, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.